DARBID Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Darbid, and what generic alternatives are available?
Darbid is a drug marketed by Glaxosmithkline and is included in one NDA.
The generic ingredient in DARBID is isopropamide iodide. There are two drug master file entries for this compound. Additional details are available on the isopropamide iodide profile page.
Summary for DARBID
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 50 |
Patent Applications: | 1,189 |
DailyMed Link: | DARBID at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for DARBID
US Patents and Regulatory Information for DARBID
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline | DARBID | isopropamide iodide | TABLET;ORAL | 010744-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |